Article Data

  • Views 749
  • Dowloads 162

Original Research

Open Access Special Issue

Short and long-term outcomes of endometrial cancer and atypical endometrial hyperplasia management in young women

  • Monika Sobočan1,2,*,
  • Dorotea Gašpar1
  • Darja Arko1,2
  • Jure Knez1,2

1Department of Gynaecology and Obstetrics, Faculty of Medicine University of Maribor, 2000 Maribor, Slovenia

2Division for Gynaecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia

DOI: 10.22514/ejgo.2022.004 Vol.43,Issue 3,June 2022 pp.91-96

Submitted: 05 January 2022 Accepted: 16 March 2022

Published: 15 June 2022

(This article belongs to the Special Issue Endometrial Cancer)

*Corresponding Author(s): Monika Sobočan E-mail: monika.sobocan@ukc-mb.si

Abstract

Objecitve: The incidence of endometrial cancer in young women is increasing. Since survival after management is in most cases excellent, the focus on long-term patient reported outcomes (PROs) is crucial. Herein we examine the characteristics and oncological and reproductive outcomes of young women with endometrial cancer. Methods: We have identified all women under 45 years of age treated at the University Medical Centre Maribor between the years 2008–2020. Women were contacted to evaluate the endometrial cancer specific PROs using the EORTC QLQ-EN24 questionnaire. Results: Endometrial cancer and atypical endometrial hyperplasia were diagnosed in women younger than 45 years in 5.1% women and in 5.3% women respectively. Fourteen women (44%) under 45 years were eligible for fertility sparing procedures and only 6 of them (43%) opted for this approach. Women who opted for fertility sparing procedures were significantly younger (p < 0.001) with a median age of 31.0 (29–35) versus 42.5 years (34–45) in women opting for standard treatment. A significant proportion of women opting for fertility sparing treatment (67%) were nulliparous (p < 0.014) at time of diagnosis. Considering PROs, a high level of reported back/pelvic pain and tingling/numbness in the limbs was reported in our group of women. Conclusions: Young women with endometrial cancer should be offered counselling on the possibility of fertility sparing procedures. Future research should focus on long term PROs and mechanisms of improving them.


Keywords

Endometrial cancer; Quality of life; Fertility sparing therapy


Cite and Share

Monika Sobočan,Dorotea Gašpar,Darja Arko,Jure Knez. Short and long-term outcomes of endometrial cancer and atypical endometrial hyperplasia management in young women. European Journal of Gynaecological Oncology. 2022. 43(3);91-96.

References

[1] Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. International Journal of Gynecologic Cancer. 2015; 25: 1010–1014.

[2] Lai C, Wang C, Chao A. The Clinical Management of Endometrial Cancer in Young Women. Current Obstetrics and Gynecology Reports. 2013; 2: 26–31.

[3] Peiretti M, Congiu F, Ricciardi E, Maniglio P, Mais V, Angioni S. Con-servative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women. Ecancermedicalscience. 2020; 13: 892.

[4] Inoue O, Hamatani T, Susumu N, Yamagami W, Ogawa S, Takemoto T, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reproductive Biology and Endocrinology. 2016; 14: 2.

[5] Maggiore ULR, Khamisy-Farah R, Bragazzi NL, Bogani G, Martinelli F, Lopez S, et al. Fertility-sparing treatment of patients with endometrial cancer: A review of the literature. Journal of clinical medicine. 2021; 10: 4784.

[6] Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA: A Cancer Journal for Clinicians. 1999; 49: 33–64.

[7] Šegedin B, Merlo S, Smrkolj Š, Bebar S, Blatnik A, Cerar O, et al. Priporočila za obravnavo bolnic z rakom materničnega telesa Reccomendations for diagnosis, treatment and follow-up of patients with endometrial carcinoma. Onkologija. 2018; 22: 96–114.

[8] Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstetrics and Gynecology. 1984; 64: 417–420.

[9] Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstetrics and Gynecology. 1981; 57: 699–704.

[10] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27: 16–41.

[11] Emons G, Beckmann MW, Schmidt D, Mallmann P. New who Classifi-cation of Endometrial Hyperplasias. Geburtshilfe Und Frauenheilkunde. 2019; 75: 135–136.

[12] Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction. 2007; 22: 1953–1958.

[13] Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, et al. Management of endometrial cancer: issues and controversies. European Journal of Gynaecological Oncology. 2016; 37: 6–12.

[14] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecologic Cancer. 2021; 31: 12–39.

[15] Shisler R, Sinnott JA, Wang V, Hebert C, Salani R, Felix AS. Life after endometrial cancer: a systematic review of patient-reported outcomes. Gynecologic Oncology. 2018; 148: 403–413.

[16] Lewin SN. Revised FIGO staging system for endometrial cancer. Clinical Obstetrics and Gynecology. 2011; 54: 215–218.

[17] Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-Franse LV, Radisic VB, et al. Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). European Journal of Cancer. 2011; 47: 183–190.

[18] Knez J, Mahdawi LA, Takač I, Sobočan M. The perspectives of fertility preservation in women with endometrial cancer. Cancers. 2021; 13: 602.

[19] Maggiore ULR, Martinelli F, Dondi G, Bogani G, Chiappa V, Evangelista MT, et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: A retrospective study. Journal of Gynecologic Oncology. 2019; 30: e57.

[20] Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. American Journal of Obstetrics and Gynecology. 2019; 221: 474.e1–474.e11.

[21] Novikova OV, Nosov VB, Panov VA, Novikova EG, Krasnopolskaya KV, Andreeva YY, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecologic Oncology. 2021; 161: 152–159.

[22] Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving Treatment in Young Women with Grade 1 Presumed Stage IA Endometrial Adenocarcinoma. International Journal of Gynecological Cancer. 2018; 28: 385–393.

[23] Park J, Seong SJ, Kim T, Kim JW, Kim SM, Bae D, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstetrics and Gynecology. 2013; 121: 136–142.

[24] Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gyneco-logic Oncology. 2012; 125: 477–482.

[25] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016; 387: 1094–1108.

[26] Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecologic Oncology. 2019; 153: 487–495.

[27] Son J, Carr C, Yao M, Radeva M, Priyadarshini A, Marquard J, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. International Journal of Gynecologic Cancer. 2020; 30: 631–639.

[28] Buchanan A, Roddy M, Badr H. Patient-reported outcomes of non-pharmacological interventions for endometrial cancer survivors: a systematic review. Journal of Cancer Survivorship. 2021; 15: 526–535.

[29] Hubbs JL, Dickson Michelson EL, Vogel RI, Rivard CL, Teoh DGK, Geller MA. Sexual quality of life after the treatment of gynecologic cancer: what women want. Supportive Care in Cancer. 2019; 27: 4649–4654.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top